Tumor antigen presentation via major histocompatibility complex class I and II on dendritic cell

Tumor antigen presentation via major histocompatibility complex (MHC) class I and II on dendritic cells is not a single molecular target but rather describes a critical immunological process. In this pathway, dendritic cells—the most potent professional antigen-presenting cells—capture tumor-associated antigens from dying or phagocytosed tumor cells within the tumor microenvironment[4][8]. These antigens are processed and loaded onto MHC molecules: • MHC class I presents peptides primarily derived from endogenous proteins or through cross-presentation of exogenous antigens. This enables activation of cytotoxic CD8+ T lymphocytes that can recognize and kill malignant cells expressing these peptide-MHC complexes[1][3][6]. • MHC class II presents peptides derived from exogenous proteins to CD4+ helper T-cells, supporting broader adaptive immune responses including help for cytotoxic T-cells and B-cell antibody production[3][4]. Dendritic cell-mediated tumor antigen presentation is essential for initiating effective anti-tumor immunity. The efficiency of this process determines whether tumors are recognized by the immune system or evade detection—a key factor in cancer progression versus successful immunotherapy responses[2][4]. Therapeutic strategies such as dendritic cell vaccines aim to harness or enhance this function by loading patient-derived DCs with tumor antigens ex vivo before re-infusion into patients[2]. Impairment in DC maturation or function within tumors is associated with poor anti-tumor responses. This entry does not correspond to an individual gene product, protein receptor, enzyme, transporter, etc., but rather refers collectively to an essential biological mechanism involving multiple molecules (including all classical MHC-I/II genes/proteins) expressed specifically on dendritic cells in the context of cancer immunity.

Other names

Antigen presentation by dendritic cellTumor antigen cross-presentationDendritic cell-mediated tumor antigen presentationDC MHC-I/II tumor antigen presentation